共查询到20条相似文献,搜索用时 31 毫秒
1.
A 14-year-old boy who was neutropenic following chemotherapy for leukemia developed fungemia caused by the yeast Kodomaea ohmeri (Pichia ohmeri). The infection was cured by catheter removal and the use of fluconazole. A 74-year-old man who had undergone surgeries for a subcutaneous tumor developed polymicrobic cellulitis involving Kodomaea ohmeri. Despite surgical debridement and antibiotic therapy, the patient died of complications. Including these 2 cases, there have been 10 Kodomaea ohmeri infections reported thus far, all occurring in patients with pre-existing conditions. There have been seven cases of fungemia and one case each of peritonitis, funguria, and cellulitis. The treatment employed varied depending on the site/source of infection. Seven patients recovered and three died. The microbiological data available suggest that Kodomaea ohmeri can be identified definitively by biochemical tests and is susceptible to amphotericin B and either susceptible to or dose dependently susceptible to itraconazole and fluconazole. 相似文献
2.
Described here is an unusual case of disseminated Cylindrocarpon lichenicola (Fusarium lichenicola) infection originating from a toenail lesion of a neutropenic woman with cellulitis of the foot and underlying acute leukaemia.
A computed tomography scan of the chest showed multiple, ill-defined, nodular infiltrates with alveolar consolidation. The
fungus was isolated from both the nail and the skin of the infected toe. Susceptibility testing revealed low minimum inhibitory
concentrations for amphotericin B (0.78 μg/ml) and voriconazole (1.56 μg/ml) and high minimum inhibitory concentrations (>100 μg/ml)
for fluconazole, ketoconazole and itraconazole. The infection resolved after treatment with a total dose of 1 g of amphotericin B
followed by oral itraconazole and bone marrow regeneration.
Electronic Publication 相似文献
3.
Martino P. Girmenia C. Micozzi A. De Bernardis F. Boccanera M. Cassone A. 《European journal of clinical microbiology & infectious diseases》1994,13(10):797-804
The association between colonization withCandida spp., subsequent occurrence of invasive candidiasis and empiric use of amphotericin B was investigated prospectively in 139 neutropenic patients with hematologic malignancies. Treatment with amphotericin B was required in 67 % of patients colonized in multiple non-contiguous body sites (multicolonized) versus 31 % of patients colonized in single or contiguous sites (monocolonized) and in 21 % of non-colonized patients (p=0.0037 and p=0.00026, respectively). Invasive candidiasis was documented in 22.2 % of multicolonized versus 4.8 % of monocolonized patients and in none of the non-colonized patients (p=0.035 and p=0.0036, respectively). Analysis of the spectrum of colonizingCandida spp. showed that multicolonized subjects were colonized with increased frequency byCandida albicans compared to monocolonized subjects, and that the association between multicolonization, invasive candidiasis and amphotericin B usage was statistically significant in patients colonized byCandida albicans but not in patients colonized by otherCandida species. The association betweenCandida multicolonization and the occurrence ofCandida infection seems to be confirmed by a double-blind placebo-controlled study performed in a small subgroup of the multicolonized patients treated with fluconazole. 相似文献
4.
Human protothecosis is a rare infection caused by members of the genus Prototheca. Prototheca species are generally considered to be achlorophyllic algae and are ubiquitous in nature. The occurrence of protothecosis can be local or disseminated and acute or chronic, with the latter being more common. Diseases have been classified as (i) cutaneous lesions, (ii) olecranon bursitis, or (iii) disseminated or systemic manifestations. Infections can occur in both immunocompetent and immunosuppressed patients, although more severe and disseminated infections tend to occur in immunocompromised individuals. Prototheca wickerhamii and Prototheca zopfii have been associated with human disease. Usually, treatment involves medical and surgical approaches; treatment failure is not uncommon. Antifungals such as ketoconazole, itraconazole, fluconazole, and amphotericin B are the most commonly used drugs to date. Among them, amphotericin B displays the best activity against Prototheca spp. Diagnosis is largely made upon detection of characteristic structures observed on histopathologic examination of tissue. 相似文献
5.
《Journal de Mycologie Médicale》2020,30(1):100916
Here, we describe an invasive infection due to Trichosporon coremiiforme in an HIV positive patient with neutropenia. The strain was first erroneously identified as Trichosporon asahii by conventional methods, but correctly identified by mass spectrometry using matrix-assisted laser desorption/ionization time-of-flight technology (MALDI-TOF MS) and ribosomal DNA sequencing. The infection was successfully resolved after antifungal treatment with amphotericin B and fluconazole. This case report is a contribution to the study of T. coremiiforme infections and reinforces its relevance as a species capable of causing invasive human infection in immunocompromised patients and also contributes to the study of its susceptibility profile against antifungal drugs. 相似文献
6.
M. Nucci N. Spector S. Lucena P. C. Bacha W. Pulcheri A. Lamosa A. Derossi M. J. Caiuby J. Macieira H. P. Oliveira 《European journal of clinical microbiology & infectious diseases》1992,11(12):1160-1162
Three cases are reported of disseminated infection due toFusarium species in severely neutropenic patients. The clinical findings in all patients included fever, painful disseminated nodular skin lesions and severe myalgia. The outcome was fatal despite early administration of amphotericin B. The portal of entry of the organism was probably the nasal sinus in two cases. 相似文献
7.
J. H. Salonen M. Rimpiläinen L. Lehtonen O.-P. Lehtonen J. Nikoskelainen 《European journal of clinical microbiology & infectious diseases》2001,20(3):179-184
The aim of the present study was to evaluate the diagnostic significance of the D-arabinitol/L-arabinitol ratio in urine
of neutropenic patients with suspected fungal infection. D-arabinitol/L-arabinitol ratios were determined in 373 serial urine
samples of 104 patients with haematological malignancies receiving empirical amphotericin B treatment for suspected invasive
fungal infection. Twenty-eight (8%) urine samples obtained from 17 (16%) patients were positive (ratio≥4). Eight (47%) patients
had positive urine samples at the initiation of empirical amphotericin B treatment and the rest from 7 to 30 days after empirical
therapy was started. Several urine samples were positive in six patients. Only one of the five patients with candidemia had
elevated D-arabinitol/L-arabinitol ratios (persistent Candida krusei fungaemia). Four patients with transient candidemia and seven patients with invasive mould infections were negative. Patients
who died during the study period had significantly higher D-arabinitol/L-arabinitol ratios than patients who survived (P=0.0002). Pneumonia was the most common manifestation of infection (53% of patients with elevated D-arabinitol/L-arabinitol
ratios) and was associated with an especially high mortality (67%). The present study shows that elevated urine D-arabinitol/L-arabinitol
ratios are common in febrile, neutropenic patients. However, the urine arabinitol test did not detect transient candidemia
at elevated levels during the course of infection. Furthermore, D-arabinitol/L-arabinitol ratios were often elevated in the
late phase of infection only. This contests the use of this test in guiding the initiation of antifungal therapy. The detection
of elevated arabinitol levels in neutropenic patients during empirical amphotericin B treatment is associated with poor prognosis. 相似文献
8.
C. Girmenia A. Micozzi C. Cartoni F. De Bernardis A. Cassone P. Martino 《European journal of clinical microbiology & infectious diseases》1999,18(1):55-58
To assess the role of Candida spp. in the etiology of neutropenic enterocolitis complicating aggressive cytotoxic chemotherapy, a dot immunobinding assay
for an immunodominant Candida mannoprotein antigen was employed in 20 patients with hematologic malignancies. Candida antigen was detected in at least one serum sample from 12 (60%) patients. Eleven (92%) patients were cured when an antifungal
agent was added to the antibacterial treatment. In eight patients a selective anticandidal therapy with fluconazole was administered
on the basis of positive Candida mannoproteinemia, and treatment was successful in all cases but one. Detection of Candida mannoproteinemia seems to be a useful diagnostic tool in patients with neutropenic enterocolitis and represents an additional
tool for selecting a less empiric, low toxic antifungal treatment with fluconazole. 相似文献
9.
C. Rieger S. Geiger T. Herold C. Nickenig H. Ostermann 《European journal of clinical microbiology & infectious diseases》2007,26(11):843-845
A neutropenic patient with acute myeloid leukaemia experienced a breakthrough infection of Trichosporon asahii during posaconazole treatment. After treatment was changed to a combination therapy with voriconazole and liposomal amphotericin
B, the infection resolved. Posaconazole works effectively as an antifungal prophylaxis and salvage therapy in rare invasive
fungal infections. This case however illustrates that breakthrough infections with T. asahii may occur during posaconazole treatment. 相似文献
10.
Candidiasis 总被引:9,自引:0,他引:9
Candida spp. are the most common fungal pathogens isolated in immunocompromised hosts, particularly cancer patients. Numerous clinical manifestations of candidiasis have been recognized, including localized infection such as oropharyngeal candidasis or focal hepatic candidiasis, and disseminated infection resulting from hematogenous spread, with or without documented fungemia. Granulocytopenic patients are particularly at risk.Candida albicans is isolated in approximately 40 % of cases of fungemia, otherCandida spp. now also commonly being isolated. The rate of morbidity and mortality secondary to candidiasis is still significant despite numerous attempts to develop better diagnostic techniques, and more effective means of chemoprophylaxis and therapy. Currently, new antifungal agents and galenic preparations of amphotericin B are being evaluated with the aim of improving the prognosis of candidiasis in immunocompromised hosts. 相似文献
11.
P. Phillips S. Shafran G. Garber C. Rotstein F. Smaill I. Fong I. Salit M. Miller K. Williams J. M. Conly J. Singer S. Ioannou 《European journal of clinical microbiology & infectious diseases》1997,16(5):337-345
A randomized trial was conducted to compare the efficacy and safety of fluconazole versus that of amphotericin B in the treatment of candidemia in non-neutropenic adults. Enrollment was stratified by disease severity (APACHE II score). Patients were randomized (1:1) to receive amphotericin B 0.6 mg/kg/day (cumulative dose 8 mg/kg) or fluconazole 800 mg intravenous loading dose, then 400 mg daily for four weeks (intravenous for at least 10 days). Patients were monitored for six months. A total of 106 patients were enrolled. A protocol amendment implemented midway through the trial required patients to be removed from the study and treated with amphotericin B if species identification indicated candidemia due toCandida glabrata orCandida krusei. Baseline characteristics were similar for the two groups; 103 patients (fluconazole, 50; amphotericin B, 53) met the major enrollment criteria. The intention-to-treat analysis indicated successful therapy in 50% of fluconazole recipients compared to 58% of the amphotericin B group (p=0.39; one-sided 95% Cl, –8 to 24%). The efficacy analysis included 84 patients (fluconazole, 42; amphotericin B, 42); successful outcomes were observed in 57% and 62% of cases in the fluconazole and amphotericin B groups, respectively (p=0.66: one-sided 95% Cl, –12 to 22%). The mortality at day 14 for the fluconazole group was 26% and for the amphotericin B group 21% (p=0.52; chi-square test) and remained similar throughout the course of follow-up. Drug-related adverse events were more frequent with amphotericin B than with fluconazole and prompted switching of therapy for two (4%) and zero cases, respectively. Fluconazole and amphotericin B were associated with similar clinical response rates and survival in the treatment of candidemia among non-neutropenic patients; however, drug-related adverse events were more frequent with amphotericin B. 相似文献
12.
T. Büchner W. Fegeler H. Bernhardt N. Brockmeyer K.-H. Duswald M. Herrmann D. Heuser U. Jehn G. Just-Nübling M. Karthaus G. Maschmeyer F.-M. Müller J. Müller J. Ritter N. Roos M. Ruhnke A. Schmalreck R. Schwarze G. Schwesinger G. Silling 《European journal of clinical microbiology & infectious diseases》2002,21(5):337-352
Now that modern medicine can provide increasing chances of cure to patients with formerly incurable disorders, therapy-related
complications play the key role in outcome. Thus, among opportunistic infections, severe candidiasis remains a challenge.
A multidisciplinary panel of 20 investigators was formed to find a consensus on antifungal strategies for various underlying
conditions in neutropenic and non-neutropenic patients. To record their preferences, the investigators used an anonymous voting
system. Among antifungal agents, fluconazole emerged as the major alternative to the classic amphotericin B, being therapeutically
at least equivalent but clearly less toxic. Factors that restrict the use of fluconazole include pretreatment with azoles,
involvement of resistant species like Candida krusei, and an inability to exclude aspergillosis. Flucytosine can be reasonably combined with both amphotericin B and fluconazole.
Within the limited antifungal armamentarium, amphotericin B lipid formulations and itraconazole also appear useful and require
further investigation. The general consensus of the group is that antifungal agents should be administered at sufficient dosages,
rather early, and often empirically.
Electronic Publication 相似文献
13.
I. Surmont B. Vergauwen L. Marcelis L. Verbist G. Verhoef M. Boogaerts 《European journal of clinical microbiology & infectious diseases》1990,9(3):226-229
Trichosporon beigelii (Trichosporon cutaneum) was identified as the causative agent of chronic meningitis in a 15-year-old boy with acute lymphocytic leukaemia. After a neutropenic episode following cytostatic treatment and itraconazole therapy as prophylaxis, cerebrospinal fluid (CSF) samples yielded growth ofTrichosporon beigelii. Treatment with amphotericin B, flucytosine and high doses of fluconazole was followed by clinical improvement, although CSF pleocytosis remained. The cross-reactivity betweenCryptococcus neoformans andTrichosporon beigelii in a cryptococcal antigen latex test was used as a means of diagnosis in CSF and serum samples. 相似文献
14.
Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology 总被引:2,自引:0,他引:2 下载免费PDF全文
Huijgens PC Simoons-Smit AM van Loenen AC Prooy E van Tinteren H Ossenkoppele GJ Jonkhoff AR 《Journal of clinical pathology》1999,52(5):376-380
AIMS: To compare the efficacy of and tolerance to oral fluconazole and intraconazole in preventing fungal infection in neutropenic patients with haematological malignancies. PATIENTS: 213 consecutive, afebrile adult patients treated with or without autologous stem cell transplantation for haematological malignancies. METHODS: A randomised, double blind, single centre study. Patients were randomly assigned to receive fluconazole 50 mg or itraconazole 100 mg, both twice daily in identical capsules. An intention to treat analysis was performed on 202 patients, 101 in each group. RESULTS: Microbiologically documented systemic fungal infections occurred in four patients in each group. Clinical fungal infection was thought to be present in seven recipients of fluconazole and four of itraconazole. In all 202 patients, 29 proceeded to intravenous amphotericin (amphotericin B), 16 in the fluconazole group and 13 in the itraconazole group. Superficial fungal infection was seen only in three non-compliant patients in the fluconazole group. All these infections were oral. No major differences were noted in the isolates of fungi in mouth washes and fecal samples. Overall mortality was 8.9% (18 deaths; seven in the fluconazole group, 11 in the itraconazole group). Mortality from microbiologically and clinically documented fungal infection was 4.5% (nine deaths; three in the fluconazole group, six in the itraconazole group). Median time to suspected or proven fungal infection was 16 days in both groups. None of these comparisons reached statistical significance (p < 0.05). No major clinical toxicity was noted and compliance was excellent. CONCLUSIONS: In neutropenic patients treated for haematological malignancies with or without autologous stem cell transplantation, fluconazole and itraconazole in low doses result in a similar low frequency of fungal disease. Fluconazole may be the preferable drug because of the smaller number of capsules and lack of need for timing relative to meals. 相似文献
15.
R. Herbrecht V. Letscher-Bru C. Fohrer F. Campos S. Natarajan-Ame A. Zamfir J. Waller 《European journal of clinical microbiology & infectious diseases》2002,21(11):814-817
A severely neutropenic patient with chronic lymphocytic leukemia developed a diffuse bilateral pulmonary infection while receiving
a therapeutic daily dosage of intravenous amphotericin B for Candida glabrata esophagitis. Computed tomography of the chest showed numerous lung nodules, ground glass areas and a pleural effusion. Biopsy
of one nodule demonstrated hyaline septate hyphae. Multiple sputum cultures grew Acremonium strictum. Increasing the dose of amphotericin B and the addition of itraconazole did not resolve the infection. Change of treatment
to posaconazole given orally at 200 mg four times/d resulted in progressive improvement leading finally to cure after 24 weeks
of therapy. Treatment with posaconazole was clinically and biologically well tolerated.
Electronic Publication 相似文献
16.
Aybüke Akaslan Kara Ümmühan Çay Rumeysa Yalçınkaya Emine Hafize Erdeniz Tuğçe Tural Kara Halil Özdemir Gizem Güner Özenen Meltem Polat Zeynep Gökçe Gayretli Aydın Gülsüm Alkan Eda Kepenekli Özlem Özgür Gündeşlioğlu Elif Kıymet Asuman Birinci Filiz Kibar Elif Böncüoğlu Zümrüt Şahbudak Bal Derya Alabaz İlker Devrim 《Journal de Mycologie Médicale》2022,32(1):101229
BackgroundInvasive Trichosporon infections are rarely seen opportunistic fungal infections in children and mainly affect immunocompromised patients. This multicenter retrospective study has rewieved the characteristics, risk factors, treatment modalities and outcomes of bloodstream infections caused by Trichosporon species in children diagnosed over the past ten years in Turkey.MethodsThe study was performed with the participation of 12 of 55 hospitals invited from Turkey. In each center, the patients with bloodstream infections caused by Trichosporon spp. between January 2010 and December 2020 were retrospectively ascertained and the results were reported to the study coordinator by means of a simple case report. Data were collected on patient demographics, underlying condition(s), treatment of.infections caused by Trichosporon spp, and 7 and 30- day mortality rates.ResultsA total of 28 cases with fungemia caused by Trichosporon spp. were included in the study. The most common underlying disease was paediatric cancers (39.3%). T. asahii infections were detected in 78.5 % (n=22) of patients. A various spectrum of antifungal treatment regimens were used including intravenous amphotericin B monotherapy in 35.7%, intravenous amphotericin B and voriconazole combination in 32.1% and intravenous voriconazole monotherapy in 28.6% of the patients. The overall mortality rate was 28.5 %. The mortality rates were 12.5% in the voricanozole, 30% in the amphotericin B and 33.3% in combined voriconazole -amphotericin B armsConclusionsInvasive Trichosporon infections with an important impact of patients quality of life are almost related to underlying diseases with an overall mortality rate of 28.5%. Voriconazole was found to be associated with lower mortality rates when compared with other treatment regimens. 相似文献
17.
J. W. van't Wout 《European journal of clinical microbiology & infectious diseases》1996,15(3):238-242
Fluconazole is an effective alternative to amphotericin B for the treatment of serious infections caused byCandida albicans. Through a literature survey of candidal infections caused by non-albicans Candida spp., 43 cases treated with fluconazole were found. The most common causative organisms wereCandida parapsilosis (14 patients),Candida glabrata (12 patients), andCandida tropicalis (11 patients). The dose of fluconazole varied from 50 to 400 mg daily. The median duration of treatment was 21 days. Overall efficacy was 77%. The efficacy against the various species was 93% forCandida parapsilosis, 50% forCandida glabrata, and 82% forCandida tropicalis. In conclusion, fluconazole is effective against the most commonnonalbicans Candida spp., although higher doses may be required for infections caused byCandida glabrata. Infections caused byCandida krusei should not be treated with fluconazole. 相似文献
18.
《Critical reviews in microbiology》2013,39(3):310-324
Mucormycosis is an emerging invasive fungal infection, primarily affecting immunocompromised patients. The disease is difficult to diagnose and mortality reaches 40% even if treated adequately. Depending on site of infection and risk factors, surgical debridement in combination with systemically active antifungal drugs are the mainstay treatment strategies. Lipid-based amphotericin B is the treatment of choice for first-line therapy while posaconazole may be a promising alternative. We performed a PubMed search on reports of patients with mucormycosis treated with posaconazole. From 2003 to 2011, 96 cases have been published. Diagnosis was based on histology alone in 2 (2.1%) and microbiological evidence in 67 (69.8%), while no data on the diagnostic approach was reported in 27 (28.1%) patients. The most frequent pathogens were Rhizopus spp. (31.2%), followed by Mucor spp. (14.6%). The site of infection was predominantly rhino-orbital (38.5%, of which 43% also had central nervous system [CNS] involvement), followed by disseminated disease (22.1%). A complete response was achieved in 62 (64.6%), partial response in 7 (7.3%) patients, and stable disease in 1 (1%). Overall mortality was 24% (lacking data for three patients). In published case reports on posaconazole treatment for mucormycosis, the drug was frequently and successfully used in combination or as second line therapy. 相似文献
19.
T. G. Jensen B. Gahrn-Hansen M. Arendrup B. Bruun 《Clinical microbiology and infection》2004,10(6):499-501
Fusarium spp. cause infections only rarely in immunologically competent hosts, but disseminated infection may occur in severely immunocompromised patients. Symptoms of disseminated infection are persistent fever, despite broad-spectrum antibacterial and antifungal treatment, associated with skin lesions, most commonly on the extremities, in 60-80% of patients. A mortality rate of 50-75% has been reported for patients with disseminated fusariosis. Despite treatment failures, amphotericin B remains the preferred drug, in part because of lack of alternatives. Voriconazole is a promising new agent, but more clinical experience is required. 相似文献
20.
E.C. Francisco J.N. de Almeida Junior F. de Queiroz Telles V.R. Aquino A.V.A. Mendes M.G.M. de Andrade Barberino P. de Tarso O. Castro T. Guimarães R.C. Hahn A.C.B. Padovan G.M. Chaves A.L. Colombo 《Clinical microbiology and infection》2019,21(7):909.e1-909.e5
ObjectivesTo provide species distribution and antifungal susceptibility profiles of 358 Trichosporon clinical isolates collected from 24 tertiary-care hospitals.MethodsSpecies identification was performed by sequencing the IGS1 region of rDNA. Antifungal susceptibility testing for amphotericin B, fluconazole, voriconazole and posaconazole followed the Clinical and Laboratory Standards Institute reference method. Tentative epidemiologic cutoff values (97.5% ECVs) of antifungals for Trichosporon asahii were also calculated.ResultsIsolates were cultured mostly from urine (155/358, 43.3%) and blood (82/358, 23%) samples. Trichosporon asahii was the most common species (273/358, 76.3%), followed by T. inkin (35/358, 9.7%). Isolation of non–T. asahii species increased substantially over the last 11 years [11/77 (14.2%) from 1997 to 2007 vs. 74/281, (26.3%) from 2008 to 2018, p0.03]. Antifungal susceptibility testing showed high amphotericin B minimum inhibitory concentrations against Trichosporon isolates, with higher values for T. faecale. The ECV for amphotericin B and T. asahii was set at 4 μg/mL. Among the triazole derivatives, fluconazole was the least active drug. The ECVs for fluconazole and posaconazole against T. asahii were set at 8 and 0.5 μg/mL, respectively. Voriconazole showed the strongest in vitro activity against the Trichosporon isolates; its ECV for T. asahii was set at 0.25 μg/mL after 48 hours' incubation.ConclusionsTrichosporon species diversity has increased over the years in human samples, and antifungal susceptibility profiles were species specific. Trichosporon asahii antifungal ECVs were proposed, which may be helpful to guide antifungal therapy. 相似文献